Skip to main
IRON

IRON Stock Forecast & Price Target

IRON Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Disc Medicine Inc. has enhanced its probability of success for the FDA approval of bitopertin to 100%, indicating strong confidence in the drug's trajectory for treating erythropoietic porphyrias, which could significantly boost revenue forecasts. The company has also identified favorable risk/reward dynamics for DISC-0974, anticipating substantial upside potential with upcoming Phase 2 data in myelofibrosis-related anemia, and adjusting near- to medium-term sales estimates up to $615 million by 2029. Furthermore, the company's receipt of a Commissioner’s National Priority Voucher for bitopertin expedites the drug's application review process, which may improve its market entry timeline and revenue generation prospects.

Bears say

Disc Medicine Inc. faces several financial challenges that contribute to a negative outlook on its stock. The company is at risk of eroded pricing power due to increased competition and potential changes in regulatory policies, which can significantly impact expected revenues and profitability. Furthermore, limited cash reserves indicate a necessity for additional capital to support development efforts, compounded by uncertainties regarding the efficacy and safety of its product candidates, which could hinder their advancement in clinical trials and ultimately affect valuation.

IRON has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Disc Medicine Inc (IRON) Forecast

Analysts have given IRON a Buy based on their latest research and market trends.

According to 10 analysts, IRON has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $114.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $114.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Disc Medicine Inc (IRON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.